Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on the Assesment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty)

Journal of the American College of Cardiology

Volumn 22, Issue 7, 1993, Pages 2033-2054

  Ryan, Thomas J ^a   Bauman, William B ^a   Kennedy, J Ward ^a   Kereiakes, Dean J ^a   King III, Spencer B ^a   McCallister, Ben D ^a   Smith Jr , Sidney C ^a   Ullyot, Daniel J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; FEMALE; HUMAN; MALE;

EID: 0027379976     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(93)90794-2     Document Type: Article

References (177)

1. National Hospital Discharge Survey: Annual Summary, 1990. National Center for Health Statistics
2. ACC/AHA Guidelines for coronary angiography: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures
3. T. Duckett Jones and rheumatic fever in 1986. T. Duckett Jones Memorial Lecture
4. ACC/AHA Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures
5. A randomized trial of coronary artery bypass surgery: quality of life in patients randomly assigned to treatment groups
6. The VA cooperative randomized study of surgery for coronary arterial occlusive disease II: subgroup with significant left main lesions
7. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina
8. Survival, myocardial infarction, and employment status in a prospective randomized study of coronary bypass surgery
9. Coronary Artery Surgery Study (CASS): a randomized trial of coronary bypass surgery: eight years follow-up and survival in patients with reduced ejection fraction
10. The evolution of medical and surgical therapy for coronary artery disease: a 15-year perspective
11. Survival following coronary artery bypass grafting in patients with severe angina pectoris (CASS): an observational study
12. Exercise testing in the Coronary Artery Surgery Study randomized population
13. ACC/AHA guidelines and indications for coronary artery bypass graft surgery a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures
14. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty
15. Ten-year completed follow-up of percutaneous transluminal coronary angioplasty: the early Zurich experience
16. Clinical outcome 5 years after attempted percutaneous transluminal coronary angioplasty in 427 patients
17. Percutaneous transluminal coronary angioplasty: report from the Registry of the National Heart, Lung, and Blood Institute
18. Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981: the National Heart, Lung, and Blood Institute Registry
19. Report of five-year outcome for 1977–1981 and 1985–1986 cohorts of the NHLBI PTCA Registry [abstract]
20. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease: Veterans Affairs ACME Investigators
21. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection
22. Percutaneous transluminal angioplasty in patients with multivessel coronary disease: how important is complete revascularization for cardiac event-free survival?
23. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry
24. Multivessel coronary angioplasty from 1980 to 1989: procedural results and long-term outcome
25. Role of new technology in balloon angioplasty
26. Evaluation of emerging technologies for coronary revascularization Participants in the National Heart Lung and Blood Institute Conference on the Evaluation of Emerging Coronary Revascularization Technologies
27. Randomized trials of percutaneous transluminal coronary angioplasty, coronary artery bypass grafting surgery, or medical therapy in patients with coronary artery disease
28. Coronary angioplasty versus coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial
29. Mortality after coronary angioplasty and coronary artery bypass surgery (the national Medicare experience)
30. Changing profiles of failed coronary angioplasty patients: impact on surgical results
31. Myocardial revascularization for chronic stable angina: analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989
32. Angioplasty versus bypass surgery for multivessel coronary artery disease with left ventricular ejection fraction ≤40%
33. Short- and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients
34. Incidence and consequences of periprocedural occlusion: the 1985–1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry
35. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty
36. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up
37. Acute occlusion in multiple lesion coronary angioplasty: frequency and management
38. Changing incidence and management of abrupt closure following coronary intervention in the new device era
39. Frequency, management, and follow-up of patients with acute coronary occlusions after percutaneous transluminal coronary angioplasty
40. In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8207 procedures
41. Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty: a quantitative arteriographic analysis
42. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile
43. Surgical management of acute myocardial ischemia following percutaneous transluminal coronary angioplasty: role of the intra-aortic balloon pump
44. Benefit of the perfusion catheter for emergency coronary artery grafting after failed percutaneous transluminal coronary angioplasty
45. Outcome after major dissection during coronary angioplasty using the perfusion balloon catheter
46. Directional coronary atherectomy for failed angioplasty due to occlusive coronary dissection
47. Emergency stenting for acute occlusion after coronary balloon angioplasty
48. Results of intracoronary stents for management of coronary dissection after balloon angioplasty
49. Effect of intracoronary stenting on intimal dissection after balloon angioplasty: results of quantitative and qualitative coronary analysis
50. Emergent use of balloon-expandable coronary artery stenting for failed percutaneous transluminal coronary angioplasty
51. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty
52. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures
53. Percutaneous support devices for high risk or complicated coronary angioplasty
54. Supported “high risk” coronary angioplasty using intraaortic balloon pump counterpulsation
55. Initial report of the National Registry of Elective Cardiopulmonary Bypass Supported Coronary Angioplasty
56. Emergency use of portable cardiopulmonary bypass
57. Effect of peripheral cardiopulmonary bypass on left ventricular size, afterload and myocardial function during elective supported coronary angioplasty
58. Failed elective percutaneous transluminal coronary angioplasty requiring coronary artery bypass surgery: in-hospital and late clinical outcome at 5 years
59. Surgical standby for coronary balloon angioplasty
60. Coronary angioplasty in the United Kingdom: report of a working party of the British Cardiac Society
61. Surgical cover for percutaneous transluminal coronary angioplasty
62. Coronary angioplasty: is surgical standby needed?
63. Surgical standby for coronary angioplasty
64. Comparison of results of percutaneous transluminal coronary angioplasty with and without selective requirement of surgical standby
65. Is immediately available in-hospital surgical backup necessary for direct infarct angioplasty [abstract]
66. Primary angioplasty for AMI performed in hospitals with and without on-site surgical backup [abstract]
67. Changing trends for surgical standby in patients undergoing percutaneous transluminal coronary angioplasty
68. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico (GISSI)
69. Randomised trial of intravenous streptokinase oral aspirin both or neither among 17187 cases of suspected acute myocardial infarction ISIS-2
70. Pre-hospital initiated vs. hospital initiated thrombolytic therapy. The Myocardial Infarction, Triage and Intervention Trial
71. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
72. Angioplasty in the patient with an evolving myocardial infarction: with and without surgical backup
73. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction
74. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock
75. ACC/AHA Guidelines for the Early Management of Patients With Acute Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures
76. Unstable angina and coronary angioplasty
77. The unstable plaque: pathophysiology and therapeutic implications
78. Clinical competence in percutaneous transluminal coronary angioplasty: a statement for physicians from the ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology
79. Guidelines for credentialing and facilities for performance of coronary angioplasty
80. 17th Bethesda Conference Adult Cardiology Training
81. Coronary angioplasty in California in 1989 [abstract]
82. Comparison of quantitative coronary angiography to visual estimates of lesion severity pre- and post-PTCA
83. “High-risk” percutaneous transluminal coronary angioplasty
84. Predictors therapeutic options and long-term outcome of abrupt reclosure
85. Causes and correlates of death after unsupported coronary angioplasty: implications for use of angioplasty and advanced support techniques in high-risk settings
86. In-hospital morbidity and mortality in patients undergoing elective coronary angioplasty
87. Short and long term outcome of diabetic patients undergoing coronary angioplasty
88. Relationship between recent rest pain and acute complications of PTCA in unstable angina [abstract]
89. In-hpspital mortality rate in the National Heart Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry
90. Percutaneous transluminal coronary angioplasty (PTCA) in the elderly patient experience in the National Heart Lung and Blood Institute PTCA Registry
91. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
92. Clinical and angiographic determinants of primary coronary angioplasty success
93. Lesion morphology and coronary angioplasty: current experience and analysis
94. ABCs of coronary angioplasty: have we simplified it too much?
95. Promises and pitfalls of new devices for coronary artery disease
96. National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry as a standard for comparison of new devices: when should we use it, and what should we compare?
97. Prediction of risk for hemodynamic compromise during percutaneous transluminal coronary angioplasty
98. A simple scoring system to predict PTCA abrupt closure [abstract]
99. Quantitative study on the size of coronary artery supplying areas postmortem
100. Prognostic value of a coronary artery jeopardy score
101. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry
102. Major complications during PTCA an analysis of 5413 cases [abstract]
103. Changing profiles and late outcome of women undergoing PTCA: a report from the NHLBI PTCA Registry [abstract]
104. The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty
105. Safety and cost effectiveness of combined coronary angiography and angioplasty
106. Safety and efficacy of percutaneous transluminal coronary angioplasty performed at time of diagnostic catheterization compared with that performed at other times
107. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
108. Coronary angioplasty; antiplatelet therapy reduces acute complications but not restenosis [abstract]
109. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty
110. Coronary angioplasty at the time of initial cardiac catheterization: “ad hoc” angioplasty possibilities and challenges
111. Restenosis after coronary angioplasty an overview
112. Recognition of restenosis: can patients be defined in whom the exercise-ECG result makes angiographie restudy unnecessary?
113. Detection of restenosis after coronary angioplasty for single-vessel disease: how reliable are exercise electrocardiography and scintigraphy in asymptomatic patients?
114. Exercise echocardiography versus thallium-201 SPECT for assessing patients before and after PTCA
115. Comparison of usefulness of high-dose dipyridamole echocardiography and exercise electrocardiography for detection of asymptomatic restenosis after coronary angioplasty
116. Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test
117. Assessment of “silent” restenosis and long-term follow-up after successful angioplasty in single vessel coronary artery disease: the value of quantitative exercise electrocardiography and quantitative coronary angiography
118. Results of repeat angiography up to eight years following percutaneous transluminal angioplasty
119. Restenosis after percutaneous transluminal coronary angioplasty (PTCA) a report from the PTCA Registry of the National Heart Lung and Blood Institute
120. Factors influencing restenosis after coronary angioplasty
121. Arterial injury and the enigma of coronary restenosis
122. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms
123. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months
124. Postangioplasty restenosis rate between segments of the major coronary arteries
125. Experimental models of coronary artery restenosis
126. The role of platelets thrombin and hyperplasia in restenosis after coronary angioplasty
127. Restenosis after successful percutaneous transluminal coronary angioplasty
128. Identifying patients at high risk for restenosis after percutaneous transluminal coronary angioplasty for unstable angina pectoris
129. Restenosis after transluminal coronary angioplasty: a risk factor analysis
130. Outcome in patients with recurrent restenosis after percutaneous transluminal balloon angioplasty
131. Importance of complete revascularization in performance of the coronary bypass operation
132. Strategy of complete revascularization in patients with multivessel coronary artery disease: a report from the 1985–1986 NHLBI PTCA Registry
133. PTCA in patients with stable angina pectoris and multi-vessel disease: is incomplete revascularization acceptable?
134. Coronary angioplasty: a therapeutic option for symptomatic patients with two and three vessel coronary disease
135. Degree of revascularization in patients with multivessel coronary disease: a report from the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasly Registry
136. Successful multiple segment coronary angioplasty: effect of completeness of revascularization in single-vessel multilesions and multivessels
137. Coronary angioplasty for patients with multivessel coronary artery disease: follow-up clinical status
138. The degree of revascularization and outcome after multivessel coronary angioplasty
139. Completeness of revascularization after coronary angioplasty and coronary surgery different strategies different results [abstract]
140. Multiple vessel coronary angioplasty: classification, results, and patterns of restenosis in 494 consecutive patients
141. Coronary angioplasty in single-vessel complex lesions: short- and long-term outcome and factors predicting acute coronary occlusion
142. PTCA of the left coronary artery when the right coronary artery is chronically occluded
143. Direct angioplasty for acute myocardial infarction: a review of outcomes in clinical subsets
144. A randomized trial of immediate versus delayed elective angioplasiy after intravenous tissue plasminogen activator in acute myocardial infarction
145. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty
146. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A Trial
147. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial
148. Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction
149. Long-term follow-up of patients treated with coronary angioplasty for acute myocardial infarction
150. Emergency percutaneous transluminal coronary angioplasty in acute myocardial infarction: a 3 year experience
151. Outcomes of direct coronary angioplasty for acute myocardial infarction in candidates and non-candidates for thrombolytic therapy
152. Myocardial salvage with direct coronary angioplasty for acute infarction
153. Initial report of the primary angioplasty revascularization (PAR) multicenter registry [abstract]
154. Comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction
155. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction
156. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction
157. Cost containment in acute myocardial infarction: evidence from a randomized trial that primary PTCA versus rt-PA reduces hospital and followup cost [abstract]
158. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy
159. Optimal therapy for cardiogenic shock: the emerging role of coronary angioplasty
160. Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival
161. Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock
162. Cardiogenic shock complicating acute myocardial infarction: the use of coronary angioplasty and the integration of the new support devices into patient management
163. Effectiveness of percutaneous transluminal coronary angioplasty in cardiogenic shock during acute myocardial infarction
164. Angioplasty therapy of cardiogenic shock: are randomized trials necessary?
165. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era
166. Emergency “rescue” percutaneous transluminal coronary angioplasty after failed thrombolysis with streptokinase: early and late results
167. Rescue coronary angioplasty after failure of intravenous streptokinase in acute myocardial infarction: in-hospital and long-term outcomes
168. Present status of rescue coronary angioplasty: current polarization of opinion in randomized trials
169. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: results of thrombolysis and angioplasty of myocardial infarction-phase 5 randomized trial
170. Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty
171. Does failed direct infarct angioplasty cause increased mortality? [abstract]
172. Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction: the Western Washington Intracoronary Streptokinase Trial
173. From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy
174. Effect of coronary angioplasty on late potentials one to two weeks after acute myocardial infarction
175. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction: analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II